Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study)

2004

Reddy, 1998, Emerging epidemic of cardiovascular disease in developing countries, Circulation, 97, 596, 10.1161/01.CIR.97.6.596

Ministerio de Salud de Chile, 1999

Kark, 2005, Myocardial infarction occurrence in Jerusalem: A Mediterranean anomaly, Atherosclerosis, 178, 129, 10.1016/j.atherosclerosis.2004.08.022

Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart Study): Case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 2001, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 111), JAMA, 285, 2486, 10.1001/jama.285.19.2486

De Backer, 2003, European guidelines on cardiovascular disease prevention in clinical practice, Eur Heart J, 24, 1601, 10.1016/S0195-668X(03)00347-6

Ito, 2001, The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events, J Cardiovasc Pharmacol Ther, 6, 129, 10.1177/107424840100600204

Athyros, 2002, Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heartdisease Evaluation (GREACE) study, Curr Med Res Opin, 18, 220, 10.1185/030079902125000787

LaRosa, 2005, Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, 1425, 10.1056/NEJMoa050461

Liao, 2002, Beyond lipid lowering: The role of statins in vascular protection, Int J Cardiol, 86, 5, 10.1016/S0167-5273(02)00195-X

Davidson, 2005, Clinical significance of statin pleiotropic effects: Hypotheses versus evidence, Circulation, 111, 2280, 10.1161/01.CIR.0000167560.93138.E7

Schwandt, 2004, Achieving lipid goals in Europe: How large is the treatment gap?, Expert Rev Cardiovasc Ther, 2, 431, 10.1586/14779072.2.3.431

Foley, 2003, Effectiveness of statin titration on lowdensity lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events, Am J Cardiol, 92, 79, 10.1016/S0002-9149(03)00474-0

Shepherd, 2003, Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals, Am J Cardiol, 91, 11C, 10.1016/S0002-9149(03)00004-3

Jones, 2003, Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial), Am J Cardiol, 92, 152, 10.1016/S0002-9149(03)00530-7

Schuster, 2004, Investigating cardiovascular risk reduction—The Rosuvastatin GALAXY Programme., Expert Opin Pharmacother, 5, 1187, 10.1517/14656566.5.5.1187

Fuentes, 2003, Blood cholesterol level and prevalence of hypercholesterolaemia in developing countries: A review of population-based studies carried out from 1979 to 2002, Eur J Cardiovasc Prev Rehabil, 10, 411, 10.1097/01.hjr.0000085247.65733.4f

Davidson, 2002, Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type Ila or IIb hypercholesterolemia, Am J Cardiol, 89, 268, 10.1016/S0002-9149(01)02226-3

1989

2002

1998, Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on coronary prevention, Eur Heart J, 19, 1434, 10.1053/euhj.1998.1243

2003

2004

Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499

Blasetto, 2003, Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups, Am J Cardiol, 91, 3C, 10.1016/S0002-9149(03)00003-1

Kritharides, 2004, Reducing low-density lipoprotein cholesterol-treating to target and meeting new European goals, Eur Heart J, 6, A12, 10.1016/j.ehjsup.2004.01.004

Strandberg, 2004, Twelveweek, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: A DISCOVERY study, Clin Ther, 26, 1821, 10.1016/j.clinthera.2004.11.015

Strandberg, 2005, DISCOVERY: A comparison of efficacy and safety of rosuvastatin and atorvastatin in high-risk subjects with hypercholesterolaemia, Int J Clin Pract, 59, 3, 10.1111/j.1368-504X.2005.0538a.x

2002, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial, Lancet, 360, 7, 10.1016/S0140-6736(02)09327-3

Sever, 2003, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0

Cannon, 2004, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583

Wiviott, 2004, Can LDL be too low? A safety analysis of the intensive treatment arm of PROVE IT-TIMI 22, Circulation, 110, 498

2001, Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme, EurHeart J, 22, 554, 10.1053/euhj.2001.2610

Rosenson, 2004, Current overview of statin-induced myopathy, Am J Med, 116, 408, 10.1016/j.amjmed.2003.10.033

Newman, 2003, Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients, Am J Cardiol, 92, 670, 10.1016/S0002-9149(03)00820-8

Brown, 2002, Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trial, Am Heart J, 144, 1036, 10.1067/mhj.2002.129312

Vidt, 2004, Rosuvastatin-induced arrest in progression of renal disease, Cardiology, 102, 52, 10.1159/000077704

Verhulst, 2004, Inhibitors of HMG-CoA reductase reduce receptormediated endocytosis in human kidney proximal tubular cells, J Am Soc Nephrol, 15, 2249, 10.1097/01.ASN.0000136778.32499.05

Brewer, 2003, Benefit-risk assessment of rosuvastatin 10 to 40 milligrams, Am J Cardiol, 92, 23K, 10.1016/S0002-9149(03)00779-3